Physician profile
Wasim E Deeb
NPI 1881700698
$285,617.41
in general payments reported to CMS, 2019-2025
79 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $17K · 2021: $58K · 2022: $56K · 2023: $19K · 2024: $27K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $16K · Consulting Fee: $2,790 · Travel and Lodging: $1,768 · Education: $89.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,246.00 |
| Food and Beverage | $16,195.88 |
| Consulting Fee | $2,790.00 |
| Travel and Lodging | $1,768.05 |
| Education | $89.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $110,865.00 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $90,543.45 | 2019-2025 | Evenity, Prolia, Tepezza |
| Astrazeneca Pharmaceuticals LP | $32,552.69 | 2019-2024 | Farxiga, Lokelma |
| Insulet Corporation | $8,880.29 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $6,732.50 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $5,376.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $4,363.58 | 2019-2023 | Steglatro, Steglujan |
| Vivus LLC | $3,317.87 | 2019-2024 | Qsymia |
| Cequr Corporation | $2,863.79 | 2024-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,540.97 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $1,400.88 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,332.66 | 2019-2024 | Cycloset |
| Mannkind Corporation | $1,280.15 | 2019-2024 | Afrezza |
| Dexcom, INC. | $1,179.26 | 2019-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $1,171.72 | 2021-2025 | Unithroid |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,103.56 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $1,018.55 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $914.78 | 2021-2025 | |
| Amarin Pharma, INC. | $759.23 | 2019-2023 | |
| Corcept Therapeutics | $754.27 | 2019-2025 | Korlym |
| Radius Health, INC. | $656.34 | 2019-2025 | Tymlos |
| Antares Pharma, INC. | $652.47 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Ibsa Pharma INC. | $523.93 | 2019-2025 | Tirosint, Tirosint, Licart |
| Endo Pharmaceuticals INC. | $488.28 | 2019-2023 | Aveed |
| Abbvie INC. | $473.10 | 2019-2025 | Synthroid |
| Tandem Diabetes Care, INC. | $460.73 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $391.48 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Madrigal Pharmaceuticals | $325.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Novartis Pharmaceuticals Corporation | $323.61 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $267.26 | 2022-2025 | Strensiq |
| Currax Pharmaceuticals LLC | $246.63 | 2020-2025 | Contrave, Nexletol, Nexlizet |
| Clarus Therapeutics INC. | $209.72 | 2021 | |
| Zealand Pharma US, INC. | $207.46 | 2020-2022 | |
| Avvisto Therapeutics, LLC | $188.28 | 2024-2025 | Cycloset |
| Kowa Pharmaceuticals America, INC. | $177.27 | 2019-2022 | |
| Bausch Health US, LLC | $162.16 | 2019-2024 | Aplenzin, Wellbutrin |
| Horizon Therapeutics Plc | $153.69 | 2021-2022 | |
| Beta Bionics, INC. | $142.49 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $140.70 | 2025 | Yorvipath |
| Valeritas, INC. | $103.52 | 2019 | |
| Sequel Med Tech, LLC | $96.19 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $90.10 | 2025 | Imcivree |
| Opko Pharmaceuticals, LLC | $89.04 | 2019-2024 | Rayaldee |
| Ascensia Diabetes Care US INC. | $86.80 | 2023-2024 | |
| Halozyme INC | $72.20 | 2023 | |
| Acerus Pharmaceuticals Corporation | $71.96 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $68.79 | 2024-2025 | Isturisa, Signifor Lar |
| Kvk-Tech, INC. | $56.76 | 2019-2022 | |
| Companion Medical, INC. | $55.29 | 2019 | |
| Esperion Therapeutics, INC. | $54.72 | 2024-2025 | Nexletol |
| Ipsen Biopharmaceuticals, INC | $49.13 | 2019-2020 | |
| Embecta Corp. | $47.25 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Arbor Pharmaceuticals, INC. | $46.29 | 2019-2020 | |
| Tolmar, INC. | $38.37 | 2025 | Jatenzo |
| Upsher-Smith Laboratories LLC | $37.20 | 2019 | |
| Lifescan, INC. | $35.92 | 2020-2021 | |
| Nalpropion Pharmaceuticals LLC | $34.54 | 2019 | |
| Kyowa Kirin, INC. | $33.28 | 2023 | Crysvita |
| Glaxosmithkline, LLC. | $33.04 | 2025 | Shingrix, Arexvy |
| Medtronic Minimed, INC. | $28.41 | 2020 | |
| Astellas Pharma US INC | $26.00 | 2025 | Veozah |
| Neurocrine Biosciences, INC. | $25.90 | 2025 | |
| Soleno Therapeutics, INC. | $21.77 | 2025 | Vykat Xr |
| Aytu Biopharma, INC. | $17.87 | 2019 | |
| Boston Scientific Corporation | $16.54 | 2025 | General - Pain Management |
| Ferring Pharmaceuticals INC. | $16.17 | 2019 | |
| Apollo Endosurgery US INC | $15.88 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.94 | 2025 | Evkeeza |
| Bigfoot Biomedical INC | $14.34 | 2022 | |
| Scynexis, INC. | $13.84 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.68 | 2023 | Nuzyra |
| Becton, Dickinson and Company | $12.89 | 2021 | |
| Smith+Nephew, INC. | $12.85 | 2022 | |
| Eisai INC. | $12.26 | 2019 | |
| Shire North American Group INC | $11.39 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasim Deeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.